by The Brazil injectable drugs market for hospitals & ambulatory settings comprises injectable drugs that are administered via intravenous, intramuscular or subcutaneous routes. Injectable drugs finds applications in treatment of wide range of acute and chronic diseases such as cancer, diabetes, cardiovascular diseases and respiratory diseases among others. The convenience of injectable drugs over oral drugs in delivering targeted drug dosage directly into the systemic circulation is boosting their demand in hospitals and ambulatory care settings.
The Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 10775.18 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Brazil Injectable Drugs for Hospitals & Ambulatory Settings are Danaher Corporation, Agilent Technologies, Thermo Fisher Scientific, CELLINK, Sony Corporation, Merck KGaA, Stratedigm Inc., Sysmex Partec GmbH, Bio-Rad Laboratories, Miltenyi Biotec, Predictive Health Diagnostics Company, Inc., ZEISS Group International, Lambert Instruments, Nikon Instruments Inc., Leica Microsystems, and Nikon Corporation. These players are focusing on new product launches and partnerships for business expansion in Brazil.
The key opportunities in the market include growing demand for biologics and biosimilars for treatment of chronic diseases. With rising cancer incidence in Brazil, demand for targeted cancer therapies is expected to surge in coming years. Further, increasing investments by large pharmaceutical companies for facility expansions in Brazil is anticipated to boost domestic manufacturing capabilities.
Globally, the Brazil injectable drugs market is witnessing expansion driven by growing geriatric population, rising incidence of chronic diseases and improving healthcare infrastructure. The market is also expected to gain from increasing adoption of self-injectable drug delivery devices for home healthcare.
Market Drivers
The growing prevalence of chronic diseases such as cancer, diabetes and cardiovascular diseases is the key factor driving the growth of Brazil injectable drugs market. It is estimated that nearly 80% of all deaths in Brazil are caused by chronic diseases. Further, increasing healthcare expenditure by the government for provision of advanced and specialized treatment drives the demand for injectable drugs in the country. Initiatives to strengthen pharmaceutical manufacturing sector in Brazil through trade agreements and investments by global players are also propelling the market growth.
PEST Analysis
Political: Brazil regulates the drugs market for hospitals and ambulatory settings to monitor drug safety and efficacy through agencies like the Brazilian Health Regulatory Agency. The government plays a major role in drug pricing.
Economic: The Brazilian economy being the ninth largest in the world benefits the injectable drugs market. However, economic uncertainties can affect healthcare spending.
Social: An aging population and rising lifestyle diseases drive the demand for injectable drugs in Brazil. Socialized healthcare allows wider access.
Technological: Advancements in drug delivery technologies improve treatment efficacy with tools like prefilled syringes and auto-injectors. Digital platforms help optimize operations.
The injectable drugs market by value is concentrated majorly in southeastern states like São Paulo and Rio de Janeiro due to their large urban populations and healthcare infrastructure. Market growth is faster in northern states because of investments to strengthen healthcare facilities in the Amazon region.
The Brazilian injectable drugs market is growing rapidly in central-west region comprising the states of Mato Grosso do Sul, Mato Grosso, Goiás and the Federal District. This is partly due to vaccination programs in rural areas and developing healthcare hubs in cities like Goiânia. The relatively underdeveloped medical services in the region offer scope for catch-up growth.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
